Wegovy plus exercise for weight loss: what the studies show
Quick answer
The creator is a woman with PCOS using semaglutide (Wegovy) for weight management, prescribed by her primary care physician after other interventions failed. She reports approximately 16.8 pounds of weight loss over roughly two to three months on doses ranging from 0.25 mg to 1 mg, consistent with expected outcomes during the titration phase of Wegovy's dosing schedule. She reports pre-existing GERD worsening on the medication, which is a recognized and clinically relevant side effect given semaglutide's effect on gastric motility.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @leahkenyon5 actually say?
Leah says she started Wegovy in mid-October at 170.4 pounds and weighed in at 153.6 pounds at the time of filming, a loss of about 16.8 pounds. She's currently on the 1 mg dose and moving up to 1.7 mg, which she calls a "maintenance dose." She credits cleaning up her eating for resolving early GI side effects like sulfur burps and diarrhea, says her heartburn has gotten worse on the medication, and specifically calls out PCOS as the reason she struggled with stubborn weight before Wegovy. She got the prescription through her primary care doctor after trying other interventions first.
She also mentions losing weight first in her face and midsection, and jokes that breast fat has been spared. Nothing in here is wildly irresponsible, but a few details deserve a closer look.
Does the science back this up?
Mostly, yes. The STEP trial data for semaglutide is solid, and the PCOS connection she describes is well-supported in the literature. Her observation about GI side effects improving with better food choices is plausible, though the evidence there is less definitive.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4 mg semaglutide lost an average of 14.9% of body weight over 68 weeks. Leah's ~10% loss at an earlier, lower dose is right in the expected range. On PCOS specifically, a 2022 meta-analysis by Jensterle et al. in Frontiers in Endocrinology found GLP-1 receptor agonists significantly reduced body weight, fasting insulin, and androgen levels in women with PCOS. Her description of "stubborn weight that would not come off" maps directly onto the insulin resistance that characterizes PCOS and that GLP-1 drugs directly address.
Her heartburn complaint is also documented. Semaglutide slows gastric emptying, and worsening gastroesophageal reflux is a recognized side effect, particularly in people with pre-existing GERD, which she says she has.
What did they get wrong (or right)?
The biggest inaccuracy is calling 1.7 mg "a maintenance dose." That's not really how Wegovy's titration schedule works. Wegovy's approved maintenance dose is 2.4 mg weekly. The 1.7 mg is a titration step, not where you stay. It's possible her doctor has a specific plan for her, but presenting 1.7 mg as a permanent stopping point could mislead viewers into thinking they're done escalating when they may not be.
Her theory that GI side effects were caused entirely by "eating bad" is partially right but oversimplified. Fatty, rich, or high-fiber foods can worsen semaglutide-related nausea and diarrhea, and dietary changes do help. But some people experience significant GI symptoms regardless of diet, especially during dose escalation. Framing it as purely a diet quality issue could cause viewers to blame themselves if side effects persist after cleaning up their eating.
On the other hand, her point about weight loss pattern (face first, then midsection) and her honest admission that she doesn't fully understand the drug's mechanism are refreshingly accurate self-assessments. She's not overclaiming.
What should you actually know?
If you have PCOS and are considering a GLP-1 medication, the evidence is genuinely encouraging, but there are things Leah's video doesn't cover. First, semaglutide is not approved specifically for PCOS. It's approved for chronic weight management (Wegovy) and type 2 diabetes (Ozempic). Use in PCOS is off-label, even if increasingly common and supported by emerging data.
Second, the heartburn issue she mentions is worth taking seriously. People with pre-existing GERD who take semaglutide should be monitored for worsening symptoms. A 2023 study by Sodhi et al. in JAMA found GLP-1 receptor agonists were associated with increased risk of gastroparesis compared to other weight loss medications. If you already have heartburn, tell your prescriber before starting.
Third, stopping Wegovy typically leads to weight regain. The STEP 4 trial (Rubino et al., 2021, JAMA) found participants regained about two-thirds of their lost weight within a year of stopping. Leah says she'll be on 1.7 mg "for however long" and admits "I don't really know how it works." That honesty is fine for a personal update video, but anyone watching should understand this is likely a long-term medication, not a short course.
Bottom line on this video
This is a personal update, not medical advice, and Leah is mostly careful about framing it that way. Her results are plausible and her experience with PCOS aligns with what researchers are finding. The two things to correct: 1.7 mg is not a maintenance dose under Wegovy's standard protocol, and GI side effects aren't purely a diet problem. Everything else she describes is consistent with how this drug actually works.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Wegovy plus exercise for weight loss: what the studies show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The creator is a woman with PCOS using semaglutide (Wegovy) for weight management, prescribed by her primary care physician after other interventions failed.
FormBlends verdict
The creator is a woman with PCOS using semaglutide (Wegovy) for weight management, prescribed by her primary care physician after other interventions failed. She reports approximately 16.8 pounds of weight loss over roughly two to three months on doses ranging from 0.25 mg to 1 mg, consistent with expected outcomes during the titration phase of Wegovy's dosing schedule. She reports pre-existing GERD worsening on the medication, which is a recognized and clinically relevant side effect given semaglutide's effect on gastric motility.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is a woman with PCOS using semaglutide (Wegovy) for weight management, prescribed by her primary care physician after other interventions failed. She reports approximately 16.8 pounds of weight loss over roughly two to three months on doses ranging from 0.25 mg to 1 mg, consistent with expected outcomes during the titration phase of Wegovy's dosing schedule. She reports pre-existing GERD worsening on the medication, which is a recognized and clinically relevant side effect given semaglutide's effect on gastric motility.
- The STEP 1 trial (Wilding et al., 2021, NEJM) showed average weight loss of 14.9% on 2.4 mg semaglutide over 68 weeks. A 10% loss at a lower dose and shorter duration, like Leah's, is consistent with expected outcomes.
- Wegovy's standard maintenance dose is 2.4 mg weekly. The 1.7 mg dose is a titration step, not a stopping point, under the FDA-approved prescribing schedule.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The STEP 1 trial (Wilding et al., 2021, NEJM) showed average weight loss of 14.9% on 2.4 mg semaglutide over 68 weeks. A 10% loss at a lower dose and shorter duration, like Leah's, is consistent with expected outcomes.
- Wegovy's standard maintenance dose is 2.4 mg weekly. The 1.7 mg dose is a titration step, not a stopping point, under the FDA-approved prescribing schedule.
- GLP-1 receptor agonists address insulin resistance directly, which is why they show particular promise in PCOS. A 2022 meta-analysis (Jensterle et al., Frontiers in Endocrinology) found significant reductions in weight, fasting insulin, and androgen levels in women with PCOS.
- Worsening heartburn on semaglutide is a real and documented risk, especially in people with pre-existing GERD. A 2023 JAMA study (Sodhi et al.) linked GLP-1 drugs to increased gastroparesis risk compared to other weight loss medications.
- Dietary changes can reduce GI side effects on semaglutide, but they do not eliminate them entirely. Blaming side effects solely on food choices could discourage people from reporting persistent symptoms to their doctor.
- The STEP 4 trial (Rubino et al., 2021, JAMA) found patients regained approximately two-thirds of lost weight within one year of stopping semaglutide, meaning this is typically a long-term medication commitment, not a temporary course.
- Semaglutide use in PCOS is off-label. Growing evidence supports it, but patients should discuss this distinction with their prescriber when evaluating options.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Leah Kenyon · TikTok creator
60.7K views on this video
I also recently started some light working out a few times a week! #wegovy #semiglutide #weightloss
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Leah Kenyon, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.